Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease

Puerner, Dominik; Hormozi, Mohammad; Weiss, Daniel; Barbe, Michael T.; Jergas, Hannah; Prell, Tino; Guelke, Eileen; Poetter-Nerger, Monika; Falkenburger, Bjoern; Klingelhoefer, Lisa; Gutsmiedl, Pia K.; Haslinger, Bernhard; Jochim, Angela M.; Wolff, Andreas; Schroeter, Nils; Rijntjes, Michel; van Riesen, Christoph; Scheller, Ute; Wolz, Martin; Amouzandeh, Ali; Ebersbach, Georg; Gruber, Doreen; Kohl, Zacharias; Maetzler, Walter; Paschen, Steffen; Perez-Gonzalez, Pablo; Rozanski, Verena; Schwarz, Johannes; Suedmeyer, Martin; Torka, Elisabeth; Wesbuer, Simone; Bornmann, Sarah; Floeel, Agnes; Ip, Chi Wang; Krause, Patricia; Kuehn, Andrea A.; Csoti, Ilona; Herting, Birgit; van de Loo, Simone; Basheer, Aniz Ahammed; Liszka, Robert; Jost, Wolfgang H.; Koschel, Jiri; Haller, Bernhard und Lingor, Paul (2023): Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease. In: Neurology, Bd. 101, Nr. 21, E2078-E2093

Abstract

Background and ObjectivesAdvanced therapies (ATs;deep brain stimulation [DBS] or pump therapies: continuous subcutaneous apomorphine infusion [CSAI], levodopa/carbidopa intestinal gel [LCIG]) are used in later stages of Parkinson disease (PD). However, decreasing efficacy over time and/or side effects may require an AT change or combination in individual patients. Current knowledge about changing or combining ATs is limited to mostly retrospective and small-scale studies. The nationwide case collection Combinations of Advanced Therapies in PD assessed simultaneous or sequential AT combinations in Germany since 2005 to analyze their clinical outcome, their side effects, and the reasons for AT modifications.MethodsData were acquired retrospectively by modular questionnaires in 22 PD centers throughout Germany based on clinical records and comprised general information about the centers/patients, clinical (Mini-Mental Status Test/Montreal Cognitive Assessment, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS], side effects, reasons for AT modification), and therapeutical (ATs with specifications, oral medication) data. Data assessment started with initiation of the second AT.ResultsA total of 148 AT modifications in 116 patients were associated with significantly improved objective (median decrease of MDS-UPDRS Part III 4.0 points [p < 0.001], of MDS-UPDRS Part IV 6.0 points [p < 0.001], of MDS-UPDRS Part IV-off-time item 1.0 points [p < 0.001]) and subjective clinical outcome and decreasing side effect rates. Main reasons for an AT modification were insufficient symptom control and side effects of the previous therapy. Subgroup analyses suggest addition of DBS in AT patients with leading dyskinesia, addition of LCIG for leading other cardinal motor symptoms, and addition of LCIG or CSAI for dominant off-time. The most long-lasting therapy-until requiring a modification-was DBS.DiscussionChanging or combining ATs may be beneficial when 1 AT is insufficient in efficacy or side effects. The outcome of an AT combination is comparable with the clinical benefit by introducing the first AT. The added AT should be chosen dependent on dominant clinical symptoms and adverse effects. Furthermore, prospective trials are needed to confirm the results of this exploratory case collection.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198